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Abstract
Despite an emerging understanding of the genetic alterations giving rise to various tumors, the mechanisms whereby most
oncogenes are overexpressed remain unclear. Here we have utilized an integrated approach of genomewide regulatory
element mapping via DNase-seq followed by conventional reporter assays and transcription factor binding site discovery to
characterize the transcriptional regulation of the medulloblastoma oncogene Orthodenticle Homeobox 2 (OTX2). Through
these studies we have revealed that OTX2 is differentially regulated in medulloblastoma at the level of chromatin
accessibility, which is in part mediated by DNA methylation. In cell lines exhibiting chromatin accessibility of OTX2
regulatory regions, we found that autoregulation maintains OTX2 expression. Comparison of medulloblastoma regulatory
elements with those of the developing brain reveals that these tumors engage a developmental regulatory program to
drive OTX2 transcription. Finally, we have identified a transcriptional regulatory element mediating retinoid-induced OTX2
repression in these tumors. This work characterizes for the first time the mechanisms of OTX2 overexpression in
medulloblastoma. Furthermore, this study establishes proof of principle for applying ENCODE datasets towards the
characterization of upstream trans-acting factors mediating expression of individual genes.
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Introduction
Medulloblastoma is the most common pediatric brain malig-
nancy. The substantial comorbidities associated with the standard
medulloblastoma treatment of resection, radiation, and chemo-
therapy necessitate the development of selective therapeutics.
While Sonic Hedgehog (Shh) pathway inhibitors have shown
promise in treating medulloblastomas exhibiting Shh pathway
hyperactivity [1], these tumors comprise only a subset of
medulloblastoma, and few consistent druggable targets have been
described among Shh-independent variants of this tumor (e.g. Wnt
subgroup, Group 3, and Group 4) [2–4]. Our previous studies
have revealed the importance of the homeobox transcription
factor OTX2 to the maintenance of non-Shh medulloblastomas
[5]. OTX2 transcriptionally regulates cell cycle genes [6,7] and
the MYC oncogene [5], thereby contributing to medulloblastoma
maintenance, and additionally can alter the dynamics of hindbrain
progenitor cell migration and proliferation [8]. This gene is
expressed ubiquitously in Shh-independent medulloblastomas
[2,5] and is required for viability by tumors of this subgroup.
OTX2 thus represents an attractive potential drug target in this
tumor type; however, as a ligand-independent transcription factor,
inhibiting its function with standard small molecule approaches is
challenging. With this in mind, we have sought to understand the
transcriptional regulation of OTX2 with the goal of identifying
strategies of pharmacologically inhibiting its expression.
Otx2 (the mouse homolog of human OTX2) exhibits a dynamic
expression pattern during embryonic development [9,10], with its
transcription being mediated by various well-characterized
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enhancers and trans-acting regulators [11–13]. Otx2 mRNA is
expressed broadly at the epiblast stage and is progressively
restricted to the anteriormost portion of the embryo as develop-
ment proceeds [9]. The boundary of Otx2 expression sharpens at
the presumptive border of the midbrain and hindbrain during
neural tube regionalization, and as the brain fully matures, Otx2
expression is further limited to the retina, pineal gland, dorsal
tectum, choroid plexus, and posterior cerebellum [9,14–16]. With
the exception of the choroid plexus and cerebellum, Otx2
expression seems to be inherited rather than induced de novo in
most brain tissues as indicated by lineage tracing of Otx2-
expressing cells [9].
Little is known about the mechanisms of OTX2 overexpression
in medulloblastoma. Although a subset of medulloblastomas
(,21%) exhibit OTX2 genomic copy number gain [5], nearly all
non-Shh medulloblastomas (,74% of all medulloblastomas)
overexpress OTX2 [2,5,17]; thus, there remains a substantial
proportion of these tumors that aberrantly express this oncogene
in the context of normal OTX2 genomic copy number. While
OTX2 is expressed in some tissues giving rise to midbrain and
hindbrain [9] as well as in a subset of cerebellar granule neuron
precursors [8,15], which are known cellular origins of medullo-
blastoma, it is unclear whether OTX2 expression is inherited from
the tumor cell of origin or rather induced over the course of
transformation. The transcriptional regulation of OTX2 in
medulloblastoma may thus reflect the regulatory landscape
sustained from a particular developmental timepoint or rather
an unrelated regulatory mechanism unique to this tumor type.
Taking a cue from its developmental regulation [18], we and
others have demonstrated that retinoic acid can repress transcrip-
tion of OTX2 [19,20] and inhibit medulloblastoma growth [19–
21]. Clinical trials have been initiated to test the benefit of
adjuvant retinoid therapy in these tumors. However, preclinical
studies indicate that retinoids may lack efficacy in orthotopic
xenografts [20], potentially due to compensatory pathways not
active in vitro or to an inability to repress OTX2 in this tissue
context. Understanding the mechanism of OTX2 repression by
retinoids could reveal strategies of reinforcing this therapeutic
effect. To this end, we have also investigated transcriptional
regulatory elements mediating retinoid-induced OTX2 repression
in medulloblastoma cells.
The identification of transcriptional regulatory elements for
individual genes is notoriously difficult [22]. While evolutionary
conservation is frequently an indicator of some functional
relevance, this parameter does not distinguish regulatory elements
active at different developmental or physiological states, and many
regulatory regions are not well-conserved [23,24]. The assessment
of DNA fragments driving reporter genes in transgenic animals,
often using conservation as a guide, has proven critical for the
mapping of developmental enhancers for various genes, including
OTX2 [11–13,22,25,26]. However, this approach is not applicable
to specific pathological entities, such as OTX2-expressing
medulloblastoma, for which there are limited animal models
amenable to transgenic reporter analysis.
In consideration of the experimental limitations to character-
izing the transcriptional regulatory regions of OTX2 in medullo-
blastoma, we have utilized an integrated approach based upon an
emerging technology, DNase-seq, that permits genomewide
mapping of active regulatory elements such as promoters,
enhancers, repressors, insulators, and locus control regions [27].
First, we mapped DNase hypersensitive (DHS) sites comprising
,400 kb surrounding the OTX2 locus, which were then
characterized for activity and specificity with reporter assays.
Minimally-required regions of DHS sites of interest were then
interrogated for the presence of transcription factor binding motifs
to identify trans-acting factors regulating OTX2 expression, which
were then experimentally validated. Finally, we investigated
datasets characterizing the epigenome of various relevant central
nervous system (CNS) tissues to draw parallels between OTX2
regulation in medulloblastoma and in the developing brain. In
addition to characterizing OTX2 regulation in this particular
context, this study also establishes a framework for hypothesis-
driven experiments derived from ENCODE data as this endeavor
continues to map chromatin modifications and other informative
characteristics of transcriptional regulatory domains.
Materials and Methods
Tissue Samples
Brain tumor cell lines and frozen primary tumor samples were
obtained from the Duke University Brain Tumor Center Tissue
Bank.
Cell culture, reporter assays, and gene expression
experiments
Medulloblastoma and glioblastoma cells were obtained from
Darell Bigner and were maintained as previously described [19].
For luciferase assays, 105 cells were plated into each well of a 24
well plate, and cells were transfected with 1.3 mg of reporter
plasmid and 67 ng of internal control plasmid pRL-CMV using
Lipofectamine 2000, and 24 hours later cells were harvested and
tested for luciferase reporter activity using the Promega Dual-
Luciferase Reporter Assay System. All luciferase assays were
carried out using transient transfection of circular plasmids. For
siRNA experiments, cells were transfected with siRNA’s at a final
concentration of 100 nM. siRNA’s were obtained from Ambion.
siRNA sequences are as follows: Scramble: GAGUCAAC-
CUUAUGAUACUtt, OTX2 #1 GGAGGUGGCACU-
GAAAAUCtt, OTX2 #2 GGACACUAAUUCAUCUGUAtt.
OTX2-targeted siRNA’s were previously validated to repress
OTX2 protein expression using the same transfection conditions
and cell lines [5]. Coordinates of DHS sites assessed for reporter
activities are summarized in Table S1. mRNA levels were
determined by qPCR using Kapa reagents and SYBR detection.
Western blotting was carried out using a standard protocol and the
following antibodies: R & D BAF1979 anti-OTX2 and Santa Cruz
FL-335 anti-GAPDH. All-trans retinoic acid and cycloheximide
was purchased from Sigma. 5-aza-29deoxycytidine was purchased
from MP Biomedicals.
DNase treatment and analysis of hypersensitive sites
Medulloblastoma and glioblastoma cell nuclei were prepared
with 1–56107 cells using NP40 concentrations optimized for each
cell line. Nuclei were treated with increasing concentrations of
DNase and then prepped for either DNase-seq or DNase-PCR as
previously described [23,27]. DNase-seq data was processed as
previously described [23]. For DNase-PCR, 9 ng of genomic DNA
was amplified by qPCR in a 20 uL reaction using Kapa reagents
and the SYBR detection method. Standard curves were generated
for each amplicon to quantify target concentration from linear Ct
values. For each DNase concentration, target concentrations of
experimental amplicons were compared to that of a DNase-
resistant region to serve as a loading control and normalize for
nonspecific DNase activity.
Transcription factor motif search
The critical 13 bp fragment of DHS 4 was extended by 6 bp in
either direction to yield a 25 bp fragment (TGTCTCCGGGAT-
OTX2 Transcriptional Regulation in Medulloblastoma
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TAATTATGGGCAC) for subsequent motif discovery. TRANS-
FAC TFblast [28], JASPAR CORE [29], JASPAR HOMEO
[29], and Consite [30] databases were queried using default
settings. Protein-DNA interacting motifs were aligned manually to
motifs identified in [31] using MapDraw. Google searches were
performed with a 5 bp sliding window for every position of the
25 bp query fragment.
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed using anti-
OTX2 (BAF1979, R & D) or IgG control antibodies using the
ChIP Assay Kit (Upstate Cell Signaling). Enriched DNA was
quantified using qPCR as described above, and DCt was
calculated relative to Line 1 primers.
Bisulfite treatment
500 ng of DNA from each sample was bisulfite-treated using the
EZ DNA Methylation Gold Kit (Zymo Research) following the
manufacturer’s protocol, and approximately 50 ng of bisulfite-
treated or untreated DNA was amplified by PCR using Faststar
Taq. Each CpG site was scored using DNAstar Seqman Software.
Methylation-specific PCR was performed on 20 ng bisulfite-
treated DNA using Platinum Taq. Primer sequences and genomic
coordinates are listed in Table S2.
Results
DNase-seq identifies a DHS site pattern unique to
medulloblastoma
In order to map the transcriptional regulatory elements of the
OTX2 gene, we performed DNase-seq on two medulloblastoma
cell lines, D341 and D721, which overexpress OTX2 independent
of genomic copy number gain [5,19,32,33]. Both of these cell lines
also express high levels of MYC (with D341 harboring genomic
copy number gain and D721 exhibiting normal MYC copy
number) [33], suggesting that these cell lines belong to the Group
3 medulloblastoma subtype [2]. Both cell lines exhibited a similar
pattern of DHS site distribution flanking the OTX2 locus, with
many shared and prominent DHS sites present from 10 kb
upstream to 80 kb downstream of the OTX2 long isoform
transcriptional start site (Figs. 1A and S1A). All such DHS sites
were highly conserved in mammals and most (with the exceptions
of DHS sites 3 and 7) were alignable in vertebrates as divergent as
Xenopus (Fig. 1 and Table S1). We noted that DNase hypersen-
sitive regions were mostly absent outside of these clustered DHS
sites (Fig. S1A) and that the canonical insulator protein, CTCF,
bound strongly to regions flanking these clustered DHS sites
(,122 kb downstream and ,50 kb upstream of OTX2, grey bars
in Fig. S1B), indicating that OTX2 regulatory regions are likely to
reside within this range. Notably, many far distal regions were
shared between medulloblastoma and other cell types (Fig. 1B)
[34], as expected for this assay.
In contrast to medulloblastoma, the vast majority of cell lines
derived from various normal and transformed tissues exhibited
minimal to no DNase hypersensitivity in the vicinity of the OTX2
gene (Fig. 1; refer to UCSC Genome Browser at http://genome.
ucsc.edu for additional cell line data), in agreement with SAGE
data indicating that OTX2 is expressed in a restricted subset of
normal tissues and tumor types (e.g. medulloblastoma and
retinoblastoma) [35]. Strikingly, many of the DHS sites in
medulloblastoma were also present in a retinoblastoma cell line
[Weri-Rb cells, data from [36]], with medulloblastoma exhibiting
only two unique DHS sites (out of 10 prominent DHS sites) at the
OTX2 locus relative to retinoblastoma, and retinoblastoma
exhibiting only four unique DHS sites (of 14 prominent DHS
sites; Fig. S1A). Finally, a Ewing’s sarcoma cell line (SK-N-MC,
data from [36]) that expresses low but detectable levels of OTX2
exhibited one shared and three unique DHS sites at this locus
relative to medulloblastoma (Fig. S1A). The correlated presence of
clustered DHS sites in OTX2-expressing cell types is suggestive of
previously-described clusters of regulatory elements (COREs) that
cooperatively dictate cell type-specific gene expression patterns
[23,24]. DNase-seq analysis of ES cells, which appear to express
OTX2 from the short isoform promoter (Fig. S1C) [10] revealed
shared proximal DHS sites with medulloblastoma but lack of
DNase hypersensitivity at medulloblastoma DHS sites 1–4 (Fig.
S1A).
Chromatin accessibility patterns are distinct between
OTX2-expressing and -nonexpressing medulloblastomas
To determine the generalizability of this DHS site landscape
among medulloblastomas, we implemented DNase-PCR (a
targeted qPCR-based assessment of DNase sensitivity) to deter-
mine the DNase sensitivity of the seven most prominent DHS sites
in a panel of medulloblastoma cell lines. To determine the
specificity of DHS sites to OTX2-expressing cell lines, we included
two cell lines that did not express OTX2 (UW228 and D324).
With the exception of DHS 2, all DHS sites identified in the OTX2
regulatory locus were DNase-hypersensitive in OTX2-expressing
cells but DNase-resistant in OTX2-nonexpressing cell lines
(Figs. 2 and S2). These findings indicate that among medulloblas-
tomas, OTX2 expression is in part regulated by differential
chromatin accessibility of regulatory regions surrounding the
OTX2 gene.
DHS 4 uniquely exhibits enhancer activity specific to
OTX2-expressing medulloblastomas
The activity of transcriptional regulatory elements can be
controlled at the level of chromatin accessibility as well as through
the activities of sequence-specific transcription factors. To measure
the activities of such trans-acting factors in medulloblastoma cells,
we assessed transcriptional regulatory function of the six validated
DHS sites. ,500 bp fragments encompassing each DHS site (see
Table S1 for genomic coordinates) were cloned into luciferase
reporter vectors and assessed for promoter activity (in the case of
proximal DHS sites 6 and 7) or enhancer activity (all DHS sites)
following transient transfection in OTX2-expressing D283 cells.
These assays measure transcriptional activity from plasmid DNA
and thus predominately reflect the activity of sequence-specific
transcription factors. DHS sites 6 and 7 demonstrated strong,
orientation-sensitive promoter activity in cooperation with a
generic enhancer (Fig. 3A). Additionally, DHS sites 1, 4, and 7
exhibited enhancer activity when driving luciferase expression
from a strong basal promoter (Fig. 3B). The specificity of these
activities was then determined in OTX2-expressing (D283, D341)
and -nonexpressing (UW228) cell lines (Fig. 3C–D). We identified
variable promoter activities of DHS sites 6 and 7 among
medulloblastoma cell lines (Fig. 3C), indicative of a role for tumor
genetic background (independent of OTX2 status) in affecting
proximal regulatory element utilization in this tumor. However,
testing activities of distal DHS sites revealed that the enhancer
activity of DHS 4 closely associated with OTX2 expression status
(Fig. 3D). These results suggest that a transcription factor
regulating the activity of DHS 4 could influence OTX2 expression
status in medulloblastoma.
Having observed that the insulator element CTCF bound to
DHS 3 (Fig. S1B), we confirmed the ability of this fragment to
OTX2 Transcriptional Regulation in Medulloblastoma
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partially block the enhancer activity of DHS 1 in a reporter assay
(Fig. 3E), indicating that the enhancer activity of DHS 1 may be
attenuated by DHS 3 in its native genomic context.
OTX2 binds to and transactivates DHS 4
Considering that DHS 4 exhibited specific and consistent
activity in OTX2-expressing medulloblastoma cells (Fig. 3C–D),
we reasoned that the activity of trans-acting factors binding to this
element may determine the transcriptional status of OTX2 in
medulloblastoma. To identify regulatory proteins mediating DHS
4 activity, we first sought to identify the critical sequence elements
of this enhancer by generating progressive deletions within this
fragment. This analysis revealed that Fragment A, a centrally-
located 13 bp sequence, was critical for DHS 4 enhancer activity
(Fig. 3F). Given the size of this sequence, it would be expected that
scanning this fragment for transcription factor binding motifs
would yield the trans-acting regulator of DHS 4, and, critically, a
manageable number of false positives. Utilizing a variety of
curated databases and manual searches, the minimally-required
13 bp sequence (which was extended by 6 bp in both directions,
see Materials and Methods) was scanned for binding sites and
high-scoring position weight matrix (PWM) matches for hundreds
of transcription factors (Fig. S3A). Of the 42 highly-scoring
transcription factors, none were expressed consistently in OTX2-
expressing medulloblastomas as detected by SAGE [35], with the
sole exception of OTX2 itself. Notably, the minimally-required
region of DHS 4 contains a highly-scoring OTX2 binding motif
(p = 1.36e24)(Fig. 3G) that exhibits a prominent DNase footprint
[37] in medulloblastoma cells (Fig. S3B), strongly implicating
direct binding of OTX2 protein to this region.
We then sought to determine the requirement of OTX2 for
DHS 4 enhancer activity. Knockdown of OTX2 with distinct
Figure 1. DNase landscape of OTX2-expressing and -nonexpressing cell lines. DNase hypersensitivity map of (A) the OTX2 locus and (B) a
region of chromosome 14 exhibiting DHS sites that are shared among the three cell lines shown. From top to bottom, tracks are as follows: Refseq
genes, D341 medulloblastoma (Medullo) cells, D721 medulloblastoma cells, H54 glioblastoma (GBM) cells, MultiZ vertebrate alignments, PhyloP
vertebrate conservation, CpG islands. Orange bars indicate regions of consistent and robust DNase hypersensitivity in the two medulloblastoma cell
lines. Grey bar indicates DHS ‘‘R’’, also found in retinoblastoma (Fig. S1A). Genomic coordinates are indicated below tracks. Carat indicates CpG island
subjected to methylation analysis (Fig. 5 and Table S2). See Fig. S1A for extended viewing range.
doi:10.1371/journal.pone.0107156.g001
Figure 2. Validation of medulloblastoma DHS sites in a cohort of OTX2-expressing and -nonexpressing cells. Nuclei of
medulloblastoma cell lines were treated with increasing concentrations of DNase (indicated as Units per reaction), and then the relative proportion
of DNA remaining at the indicated regions were determined by qPCR. Open and solid markers indicate OTX2-expressing and -nonexpressing cell
lines, respectively. See Fig. S2 for detailed graphs.
doi:10.1371/journal.pone.0107156.g002
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siRNA’s completely abolished enhancer activity of DHS 4 in
OTX2-expressing medulloblastoma cells (Fig. 4A). As a control
for OTX2 knockdown, we utilized the OTX2-regulated fragment
of the MYC promoter, Del-3 [5], cloned into the pBV reporter
plasmid, which responded similarly to OTX2 inhibition.
To determine the ability of OTX2 to enhance its own
expression from the native OTX2 locus, we then overexpressed
EGFP-tagged OTX2, which migrates more slowly during SDS-
PAGE electrophoresis, to determine the effect of ectopic OTX2
upon expression of the endogenous OTX2 gene. In OTX2-
expressing medulloblastoma cells, we found that ectopic OTX2
indeed enhanced the expression of endogenous OTX2 (Fig. 4B).
In contrast, ectopic OTX2 did not enhance endogenous OTX2
expression in medulloblastoma cells that do not normally express
OTX2 (Fig. 4C), indicating that the appropriate cellular context is
required for OTX2 autoregulation. Induction of the OTX2 target
gene IL-6 (Fig. 4D) [6,7] in this experiment suggests that ectopic
OTX2 is indeed functional in the transfected cells. As validation
that autoregulation is not an overexpression artifact, chromatin
immunoprecipitation of endogenous OTX2 specifically enriched
the DHS 4 fragment in OTX2-expressing medulloblastoma cells
(Fig. 4E).
OTX2 promoter methylation is sufficient to inhibit OTX2
expression in medulloblastoma
Independent of distal chromatin accessibility and the activity of
trans-acting factors, OTX2 expression could also be regulated by
promoter DNA methylation. To this end, we determined the
Figure 3. Functional assessment of DHS sites. Luciferase assays measuring (A) orientation-sensitive promoter activity of proximal (,2 kb from
the TSS) DHS sites in D283 cells, (B) enhancer activity of all DHS sites in D283 cells, (C) promoter activity of functionally-validated proximal DHS sites
[underlined in (A)] in OTX2-expressing (D283, D341) and -nonexpressing (UW228) medulloblastoma cells, (D) enhancer activity of functionally-
validated DHS sites [underlined in (B)] in OTX2-expressing (D283, D341) and -nonexpressing (UW228) cells, (E) insulator activity of DHS 3 in OTX2-
expressing medulloblastoma cells, and (F) enhancer activity of minimal fragments and deletion mutants of DHS 4 in OTX2-expressing
medulloblastoma cells. (G) Alignment of the critical Fragment A region of DHS 4 with the OTX2 position weight matrix [28]. *p,0.05 relative to empty
vector, **p,0.01 relative to empty vector, {p,0.05 relative to DHS 1.pro, {{p,0.01 relative to DHS 1.pro, Student’s t-test. Error bars indicate standard
deviation.
doi:10.1371/journal.pone.0107156.g003
Figure 4. OTX2 regulates its own expression through the DHS 4 enhancer. (A) Luciferase assay for enhancer activity of DHS 4 in OTX2-
expressing medulloblastoma cells treated with OTX2 siRNA. (B) Western blotting for ectopic and endogenous OTX2 following transfection of (B)
OTX2-expressing or (C) OTX2-nonexpressing medulloblastoma cells with EGFP-tagged OTX2. (D) RT-qPCR demonstrating induction of the OTX2
target gene IL-6 in OTX2-nonexpressing medulloblastoma cells transfected with EGFP-tagged OTX2. (E) Chromatin immunoprecipitation of
endogenous OTX2 in OTX2-expressing and -nonexpressing medulloblastoma cells. *p,0.05 relative to scramble siRNA (A) or vector control (D), **p,
0.01 relative to scramble siRNA (A) or vector control (D), {p,0.05 relative to pGL3pro, {{p,0.01 relative to pGL3pro, Student’s t-test. Error bars
indicate standard deviation.
doi:10.1371/journal.pone.0107156.g004
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methylation status of OTX2 by bisulfite sequencing in a cohort of
medulloblastomas. The OTX2 locus is tiled with a number of CpG
islands, the largest of which spans the region 200 bp to 2.2 kb
downstream of the OTX2 long isoform TSS (Fig. 1A). This CpG
island is distinct from proximal DHS sites described herein.
Bisulfite sequencing of this element revealed the binary nature of
OTX2 promoter methylation status (Fig. 5A, Table S2), with 30%
of tumors exhibiting promoter methylation and 70% exhibiting a
predominately unmethylated promoter (n = 33), which was sup-
ported by methylation-specific PCR (Table S2). There was a clear
association between promoter methylation and OTX2 repression
(R = 20.5755, p = 0.0005, Spearman’s rho, Fig. 5B), with frequent
OTX2 expression (19/23; $2-fold increased relative to normal
cerebellum by qPCR; see red boxes in Fig. 5A) among tumors
harboring an unmethylated OTX2 promoter and absent OTX2
overexpression (0/10; see green boxes in Fig. 5A) among samples
exhibiting a methylated promoter (Fig. 5B). Finally, we deter-
mined that reversal of promoter methylation by treatment with 5-
aza-29deoxycytidine partially rescues OTX2 expression (Fig. 5C),
indicating that promoter methylation actively represses OTX2. In
sum, these results indicate that OTX2 promoter methylation is
sufficient for gene repression in medulloblastoma, and that an
unmethylated promoter is necessary (but not sufficient) to permit
OTX2 expression. Thus, OTX2 expression in medulloblastoma
requires both positively-acting transcriptional regulators as well as
a lack of OTX2 promoter methylation.
The chromatin landscape of OTX2 in medulloblastoma
resembles that of the embryonic brain
Given the accumulation of chromatin structure data for a
variety of tissue contexts, we then sought to compare the
regulatory landscape of OTX2 in medulloblastoma with that of
related CNS tissues. To this end, we mapped medulloblastoma
DHS sites onto the mouse genome and investigated relevant
chromatin characteristics of these elements in publically-available
genome browser tracks [36,38]. To determine chromatin states of
DHS sites in the context of dynamic OTX2 regulation, we focused
on embryonic day 14.5 (E14.5) whole brain (which includes
forebrain, midbrain, and hindbrain) and adult cerebellum. This
comparison revealed that regions orthologous to DHS sites 1, 4, 6,
7, and ‘‘R’’ exhibit DNase hypersensitivity in the E14.5 whole
brain and, to a lesser extent, adult cerebellum (Fig. S4). As
combinatorial histone modification patterns have been demon-
strated to associate with distinct regulatory activities [39],
predicted functions of regions orthologous to medulloblastoma
DHS sites were determined (Table S1) using the parameters
described in [39]. Specifically, the presence of H3K4me3 and
H3K27Ac at open chromatin proximal (,2 kb) to a TSS is
indicative of an active promoter, whereas H3K4me1 and
H3K27Ac at open chromatin distal to a TSS is indicative of a
strong enhancer. As expected, known enhancers driving forebrain
and midbrain OTX2 expression exhibited strong H3K4me1 and
H3K27Ac signals in the E14.5 brain (pink bars in Fig. S4),
supporting the potential for chromatin state to predict regulatory
function. Strikingly, chromatin states of mouse embryonic whole
brain or adult cerebellum (Table S1, Fig. S4) accurately predicted
the functional status of DHS sites in medulloblastoma (as assayed
in Fig. 3C–D), with the one exception of DHS 5 (Table S1). These
results indicate that a cell population in the developing brain, and
to a lesser extent that of the mature cerebellum, exhibits an OTX2
regulatory landscape similar to medulloblastoma.
DHS ‘‘R’’ mediates retinoid-induced OTX2 repression in
medulloblastoma
Retinoids are known to repress Otx2 during anterior-posterior
embryonic patterning [18] and when added to cultured medul-
loblastoma cells [19,20], and thus have been considered a
potential therapeutic agent for medulloblastoma. Comparison of
DHS sites among cell lines revealed a prominent DHS (DHS ‘‘R’’)
in retinoblastoma located between DHS sites 3 and 4 (Figs. 1 and
S1A) that is present at variable intensity in medulloblastoma cells
(Fig. 6A) and whose ortholog is bound in the mouse eye by the
retinal transcription factor Crx (Fig. S4) [40]. Considering the
potential role of retinoids in regulating OTX2 in the eye, these
observations led us to investigate the role of the DHS ‘‘R’’
regulatory element in retinoid-induced repression of OTX2 in
medulloblastoma. Luciferase assays measuring the transcriptional
regulatory activity of DHS ‘‘R’’ revealed that this element
represses transcription from a minimal promoter following retinoic
acid treatment (Fig. 6B). These results are consistent with a model
in which the repressor activity of DHS ‘‘R’’ is poised in
medulloblastoma cells and becomes activated following retinoid
treatment. Retinoid-induced OTX2 repression requires transla-
tion of an unknown intermediate (Fig. 6C) as indicated by
circumvention of OTX2 repression in the presence of a translation
inhibitor, cycloheximide (CYHEX), suggesting that OTX2 is not
directly regulated by retinoic acid receptors but rather through
induction of a currently-unknown transcriptional repressor. These
observations form a model in which retinoids stimulate expression
of a protein that mediates repressor activity of DHS ‘‘R’’.
Discussion
In this study, we have implemented a genomewide approach to
describe for the first time the mechanisms of basal and retinoid-
repressed OTX2 transcription in medulloblastoma, thus contrib-
uting to the understanding of critical events in both medulloblas-
toma tumorigenesis and its response to differentiation therapy.
While OTX2 genomic copy number gain is known to drive
aberrant OTX2 expression in a subset (,21%) of medulloblas-
tomas [5,19,32,33], alternative mechanisms of OTX2 overexpres-
sion have not been previously described. Here we have revealed
various complementary observations that build a model of basal
OTX2 overexpression in the absence OTX2 genomic alterations.
First, OTX2 expression associates with accessible chromatin
regions and unmethylated promoter DNA at the OTX2 locus,
indicating that DNA accessibility limits OTX2 expression to a
restricted set of normal and transformed tissues. Additionally,
OTX2 protein directly activates the only OTX2 regulatory
element that is specifically active in OTX2-expressing medullo-
blastomas. Finally, OTX2 enhancers in medulloblastoma are
marked by activating histone modifications in the embryonic
brain. These observations suggest that an OTX2 autoregulatory
loop engages developmental enhancers to drive aberrant OTX2
expression in medulloblastoma.
Could OTX2 expression be inherited from the medulloblasto-
ma cell of origin? OTX2 is expressed in the presumptive hindbrain
[9], the tissue from which medulloblastoma arises, and here we
have revealed parallels between regulatory element activities in
medulloblastoma and corresponding histone modifications in the
developing brain. An alternative cause of OTX2 expression in
these tumors would be that OTX2 is upregulated over the course
of transformation through the acquisition of developmental or
novel regulatory regions, as recently described for breast cancer or
T-cell leukemia [36]. However, given that OTX2 itself is required
for activation of the key DHS 4 enhancer in medulloblastoma, it
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would be unlikely for OTX2 to be transcriptionally re-activated
through this enhancer in the absence of OTX2 protein.
Furthermore, we have demonstrated that medulloblastoma cells
not expressing OTX2 are refractory to OTX2 transcriptional
activation through trans-acting factors. Thus, failure to repress
OTX2 during development could be the critical determinant of
OTX2 expression status in medulloblastoma. Notably, this
prediction does not rule out the involvement of mediators that
cooperate with OTX2 to modulate DHS 4 activity. The role of
such factors, including chromatin modifiers and OTX2-interact-
ing proteins, remains to be determined.
The identification of a positive feedback loop maintaining
OTX2 expression in medulloblastoma suggests that disruption of
this loop is a requisite step in the repression of OTX2 during
neural development. The mechanisms of developmental OTX2
repression that may fail during medulloblastoma tumorigenesis are
currently unclear. The existence of medulloblastomas that lack
both OTX2 expression and promoter methylation indicates that
Figure 5. Methylation of the OTX2 promoter is sufficient to suppress OTX2 in medulloblastoma. (A) Representative methylation patterns
of medulloblastoma samples, with samples organized by row and each CpG location organized in columns. Leftmost column indicates OTX2
expression status (red, OTX2-expressing; green, OTX2-nonexpressing), letters to the right of this column indicate OTX2 copy number status (N,
normal; G, gained; HL, heterozygous loss), if known [5,19,32,33]. (B) OTX2 mRNA level, as determined by RT-qPCR, in tumors exhibiting either a
methylated or unmethylated OTX2 promoter. ND, not detected. (C) Semi-quantitative RT-PCR of OTX2-nonexpressing cells treated with the indicated
concentrations of 59-aza-29-deoxycytidine for 5 days. D283 medulloblastoma cells serve as a positive control for OTX2 detection.
doi:10.1371/journal.pone.0107156.g005
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DNA methylation is unlikely the initiator of OTX2 repression
during development, but rather serves as reinforcement of a
repressive chromatin state, as previously demonstrated for other
loci [24,41]. Known developmental repressors of OTX2 in the
hindbrain include Gbx2 [42] and Fgf8 [43]; however, these genes
are rarely expressed in established medulloblastomas (Fig. S5)
[35]. Although the dynamic interplay of these mediators of OTX2
repression during medulloblastoma initiation are currently un-
known, an improved understanding of the cellular origins of this
tumor and the developmental regulation of OTX2 therein should
clarify these remaining questions regarding the molecular patho-
genesis of OTX2-driven medulloblastoma.
The importance of Otx2 to myriad aspects of vertebrate
patterning [9,14,44] has led to intense investigation of its
regulation throughout development. These efforts have led to
the mapping of various functional enhancers mediating Otx2
expression at many developmental stages (Summarized in Fig. S3
and Table S3) [11–13,25,26,45]. In many cases, the trans-acting
factors responsible for stage- and domain-specific Otx2 expression
have also been identified, and for the midbrain/hindbrain
boundary, a definitive model of Otx2 regulation has been
constructed [26]. However, the expression patterns of known
trans-acting Otx2 developmental regulators cannot in any case
explain the expression pattern of OTX2 in medulloblastoma (Fig.
S5), and mapping all previously-described Otx2 developmental
enhancers onto the human genome reveals minimal overlap
between these enhancers and medulloblastoma DHS sites (Fig.
S1A). Conversely, when functionally-validated medulloblastoma
DHS sites were mapped onto the mouse genome, these sites
frequently overlapped with signatures of promoter or enhancer
elements in the embryonic brain and adult cerebellum (Fig. S4). It
is likely that these elements are functional but have not yet been
characterized with reporter assays at this domain and develop-
mental stage. Thus, the transcriptional regulatory elements
identified here have not been previously characterized in mouse
development or otherwise.
The effect of retinoids upon medulloblastoma has been
appreciated for some time [19–21,46], and clinical trials imple-
menting retinoid treatment as an adjuvant therapy for medullo-
blastoma are underway. However, the resistance of medulloblas-
toma cells to retinoids in some experimental settings [20]
necessitates further study of the intermediates of retinoid-induced
growth arrest in this tumor type. Such investigations could identify
alternative or cooperative approaches to inducing the downstream
antitumor effects of retinoids, such as BMP2 secretion and OTX2
repression [20,21]. In this study, we have identified the
transcriptional regulatory element responsible for OTX2 repres-
sion by retinoids. Although the trans-acting factor mediating the
repressor activity of this element is unknown, Crx has been shown
to bind to this regulatory element in the mouse eye (Fig. S4) [40].
Figure 6. DHS ‘‘R’’ mediates retinoic acid-induced OTX2 repression. (A) DNase sensitivity of DHS ‘‘R’’ in three OTX2-expressing (D283, D341,
D721) and two OTX2-nonexpressing (D324, UW228) medulloblastoma cell lines. (B) Luciferase assays measuring enhancer activity of DHS ‘‘R’’
following treatment with 2 mM all-trans retinoic acid (ATRA) for 24 hours. (C) OTX2 mRNA level as determined by qPCR of medulloblastoma cells
treated with 2 mM all-trans retinoic acid (ATRA) and/or 35 mM cycloheximide (CYHEX) for 8 hours. *p,0.05 relative to DMSO, **p,0.01 relative to
DMSO, Student’s t-test. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0107156.g006
OTX2 Transcriptional Regulation in Medulloblastoma
PLOS ONE | www.plosone.org 9 September 2014 | Volume 9 | Issue 9 | e107156
Future studies implementing the approach described herein would
clarify the role of CRX or other transcription factors in mediating
the effect of retinoids upon OTX2.
The identification of cis-regulatory elements in the genome is of
broad interest and has countless potential applications in basic and
translational research. Through the ENCODE project, massive
efforts have been undertaken to characterize the regulatory
landscape of the human genome in various cell types and disease
states [24,36,37,47]. Considering the wealth of chromatin
structure data generated through such endeavors, the extension
of these studies into validated regulatory relationships has only just
begun. Determining the underlying transcriptional regulation of
single genes, certainly a frequently-pursued goal, requires a
focused approach combining reporter assays, transcription factor
motif searches, and functional validation, as demonstrated by our
current studies. Unsurprisingly, there are few successful examples
of de novo identification of distal-acting transcriptional regulators
in mammalian cell lines, with many such approaches relying upon
sequence conservation as a guide [48] or the concerted efforts
undertaken to study some of the best-characterized loci in the
genome, such as CFTR [49] and IgH [50]. Here we have
implemented a hybrid approach combining genome-wide DNase-
seq data with conventional gene regulatory assays to identify and
functionally define long-range regulatory elements mediating
transcription of a gene of interest. Our work thus serves as a
guide for future studies intended to validate transcriptional
regulatory relationships implicated through growing datasets from
the ENCODE project. This approach will be further strengthened
as transcription factor binding site motifs are accurately deci-
phered for all of the ,1500 transcription factors encoded in the
human genome. Additionally, the expansion of cell lines and tissue
types assessed for DNase hypersensitivity or similar broadly-
informative assays such as FAIRE-seq or Hi-C will enable such
studies of essentially any gene under myriad physiological
conditions.
Supporting Information
Figure S1 Comparison of OTX2 transcriptional land-
scapes in various OTX2-expressing cell types. (A) DNase
hypersensitivity landscape in OTX2-expressing and -nonexpres-
sing cell lines, wide viewing window. From top to bottom, tracks
are as follows: known mouse enhancers (as summarized in Table
S3), UCSC Genes, D341 medulloblastoma (Medullo) cells, D721
medulloblastoma cells, Weri-Rb retinoblastoma cells from [36],
SK-N-MC Ewing’s Sarcoma cells from [36], H1 embryonic stem
(ES) cells, MultiZ vertebrate alignments, PhyloP vertebrate
conservation. Green bars indicate regions of consistent and robust
DNase hypersensitivity in the two medulloblastoma cell lines. The
grey bar indicates DHS ‘‘R’’, which is a DHS site in
retinoblastoma cells and is utilized as a regulatory element in the
retina. (B) CTCF binding in OTX2-expressing cell lines as
determined by ChIP-seq. Grey bars indicate CTCF-bound
elements, and the green bar indicates CTCF binding at
medulloblastoma DHS 3. (C) Pol2 binding in cell lines
predominately expressing short or long isoforms of OTX2 (ES
cells and medulloblastoma, respectively) as determined by ChIP-
seq.
(PDF)
Figure S2 Validation of medulloblastoma DHS sites in a
cohort of OTX2-expressing and -nonexpressing cells.
Refers to Fig. 2. Nuclei of medulloblastoma cell lines were treated
with increasing concentrations of DNase, and then the relative
proportion of DNA remaining at the indicated regions were
determined by qPCR. Open and filled markers indicate OTX2-
expressing and -nonexpressing cell lines, respectively. (A) DHS 1,
(B) DHS 2, (C) DHS 3, (D) DHS 4, (E) DHS 5, (F) DHS 6, (G)
DHS 7, and (H) positive control DHS. Rxn, Reaction. Error bars
indicate standard deviation.
(PDF)
Figure S3 Identification of transcription factor binding
sites in DHS 4. (A) Summary of database search results for
transcription factor binding motifs in the critical 13 bp and 12 bp
flanking sequence (see Materials and Methods) of DHS 4. (B)
Evidence for a DNase footprint at the OTX2 binding motif of
DHS 4 in medulloblastoma cells. ‘‘Density’’ tracks refer to
smoothened data (as described in [23]), whereas ‘‘Raw’’ tracks
refers to data without smoothening.
(PDF)
Figure S4 Cross-species comparison of the OTX2 tran-
scriptional landscape in medulloblastoma and CNS
tissues. Chromatin structure of the mouse Otx2 locus. From
top to bottom, tracks are as follows: known Otx2 developmental
enhancers as determined by transgenic mouse reporter assays,
regions of homology to medulloblastoma DHS sites, Refseq genes,
CRX ChIP-seq of mouse eye [40], E14.5 whole mouse brain
DNase-seq, Pol2 ChIP-seq, H3K4me1 ChIP-seq, H3K4me3
ChIP-seq, H3K27Ac ChIP-seq, CTCF ChIP-seq, from [38] and
the UCSC Genome Browser, adult (8-week-old) cerebellum
DNase-seq, Pol2 ChIP-seq, H3K4me1 ChIP-seq, H3K4me3
ChIP-seq, H3K27Ac ChIP-seq, CTCF ChIP-seq, from [38] and
the UCSC Genome Browser, Multiz vertebrate alignment, PhyloP
vertebrate conservation. Green bars indicate medulloblastoma
DHS sites harboring marks of enhancer or promoter elements,
pink bars indicate known brain enhancers, grey bar indicates DHS
‘‘R’’.
(PDF)
Figure S5 Assessment of gene expression data for OTX2
regulators proposed in the literature. (A) Characteristics of
each proposed regulator, direction (activator or repressor) of
regulation, the proposed tissue domain of OTX2 regulation, cis-
element regulated (of elements mapped in Fig. S4), transcription
factor family, reference, p-value from two-tailed Student’s t-test
comparing expression in OTX2-positive (n = 19) and OTX2-
negative (n = 8) medulloblastomas as determined by SAGE,
Spearman’s rho correlation R value and p-value (as indicated in
parentheses) with OTX2 in medulloblastomas as determined by
SAGE [35]. *previously implicated in medulloblastoma: Chd7 [3],
Lef1 [2], Tcf7 [2], Smad3 [51], Hes1 [52], Suz12 [3]. References
for developmental regulation of Otx2: Chd7 [53], Oct4/Pou5f1
[54], Rax [55], Lef1 [26], Yy1 [56], Brn1–4 [26], Tcf7 [13],
Smad3 [57], Sox2 [54], Gbx2 [26], Eed [58], Crx [59], Hes1 [55],
Suz12 [60], Snail [61]; {expression pattern reversed relative to
expected relationship based on directional (activator or repressor)
activity; ND, not determined; V/M/C, Anterior visceral endo-
derm, anterior mesendoderm, cephalic neural crest; FB/MID,
forebrain/midbrain; MB, medulloblastoma. (B–D) Expression
patterns of the most highly significant repressors and activators
sorted by OTX2 expression level demonstrating that comparisons
or correlations are largely driven by outliers in each case (as
indicated with asterisks). MYC expression pattern is provided in
(E) as an example of a gene exhibiting a known regulatory
relationship [5] and correlation with OTX2 (R = 0.49, p = 0.009,
Spearman’s rho).
(PDF)
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Table S1 Summary of DHS characteristics.
(PDF)
Table S2 Bisulfite sequencing and methylation-specific
PCR results for 33 medulloblastomas.
(XLS)
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